

# Phase 2a Multiple Ascending Dose Study in Hospitalized Patients With Pneumonia.

NCT05123755

---

Status	RECRUITING
Phase	Phase 2
Sponsor	Vasomune Therapeutics, Inc.
Enrollment	120 participants

## Key Eligibility Criteria

---

### Inclusion (14)

- Able and willing to give signed informed consent
- Patients hospitalized with a presumed diagnosis of pneumonia of  $\leq$  48 hours duration requiring supplemental oxygen therapy. Eligible patients include those hospitalized for a separate non-infectious reason who subsequently develop a presumed pneumonia;
- Radiologic imaging (chest x-ray, CT scan, etc.) evidence of pulmonary involvement with new and persistent or progressive and persistent infiltrate, consolidation or cavitation.
- Signs and symptoms:
- At least 1 of the following signs:  
... and 9 more (see full listing online)

### Exclusion (18)

- Pregnant and/or lactating women
- Patients included in any other interventional trial
- Use of endotracheal intubation and mechanical ventilation or extracorporeal membrane oxygenation (ECMO) at screening
- Any concurrent serious medical condition or concomitant medication that would preclude participation in the study including but not limited to:
- Septic shock as defined by systolic blood pressure (SBP)  $\leq$  90 mmHg or diastolic blood pressure (DBP) of  $\leq$  60 mmHg;  
... and 13 more (see full listing online)

## Locations (5 total)

---

Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States  
Denver Health Medical Center, Denver, Colorado, United States  
MedStar Health Research Institute, Inc., Hyattsville, Maryland, United States  
... and 2 more locations